Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06EHX
|
|||
| Former ID |
DIB016019
|
|||
| Drug Name |
TAK-935
|
|||
| Indication | Dravet syndrome [ICD-11: 8A61.11] | Phase 2 | [1] | |
| LennoxGastaut syndrome [ICD-11: 8A62.1] | Phase 2 | [1] | ||
| Tuberous sclerosis [ICD-11: LD2D.2; ICD-10: Q85.1] | Phase 2 | [1] | ||
| Glutamate excitotoxity [ICD-11: 5C73; ICD-10: T36-T65] | Phase 1 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H23N3O2
|
|||
| Canonical SMILES |
C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4
|
|||
| InChI |
1S/C23H23N3O2/c27-22(20-7-4-12-25-21(20)19-8-13-24-14-9-19)26-15-10-23(28,11-16-26)17-18-5-2-1-3-6-18/h1-9,12-14,28H,10-11,15-17H2
|
|||
| InChIKey |
XKUZMIUSBMCVPP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1429505-03-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholesterol 24-hydroxylase (CYP46A1) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Primary bile acid biosynthesis | |||
| Pathwhiz Pathway | Bile Acid Biosynthesis | |||
| Reactome | Endogenous sterols | |||
| WikiPathways | Metapathway biotransformation | |||
| Oxidation by Cytochrome P450 | ||||
| Phase 1 - Functionalization of compounds | ||||
| Bile acid and bile salt metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02201056) Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935. U.S. National Institutes of Health. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040983) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.